Physician profile
Fazel Dinary
NPI 1912347360
$5,663.55
in general payments reported to CMS, 2019-2025
21 companies · $862 in 2025
The $862 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $218 · 2021: $223 · 2022: $276 · 2023: $2,225 · 2024: $1,360 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,054 · Food and Beverage: $1,587 · Consulting Fee: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,053.62 |
| Food and Beverage | $1,587.12 |
| Consulting Fee | $805.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ovesco Endoscopy USA, INC. | $1,047.42 | 2024 | |
| Conmed Corporation | $988.66 | 2023 | Gore Viabil, Conmed Generators, Conmed Biliary |
| Olympus Corporation of The Americas | $818.92 | 2023 | Single Use Electrosurgical Knife Kd-655, Single Use Electrosurgical Hemostatic Forceps, Disposable Distal Attachment |
| Boston Scientific Corporation | $566.02 | 2019-2025 | Spyglass, Spyglass Discover, Jagtome Rx 39 |
| Braintree Laboratories, INC. | $509.83 | 2023-2025 | Sutab, Suflave |
| Apollo Endosurgery US INC | $399.44 | 2019 | |
| Olympus America INC. | $252.19 | 2020-2025 | Endoclot Phs |
| Micro-Tech Endoscopy USA, INC. | $229.01 | 2023 | Goldknife |
| Covidien Lp | $170.93 | 2020 | |
| Mallinckrodt Hospital Products INC. | $143.75 | 2023 | Terlivaz |
| Medtronic, INC. | $129.77 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $63.73 | 2022-2024 | Dupixent |
| Vivus LLC | $62.53 | 2024-2025 | Qsymia |
| Aimmune Therapeutics, INC. | $51.60 | 2024 | |
| Abbvie INC. | $50.21 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $41.77 | 2022 | |
| Celgene Corporation | $41.49 | 2024 | Zeposia |
| Madrigal Pharmaceuticals | $26.24 | 2025 | Rezdiffra |
| Pfizer INC. | $25.03 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.52 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $21.49 | 2024 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fazel Dinary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.